Beam Therapeutics (BEAM) Revenue & Revenue Breakdown
Beam Therapeutics Revenue Highlights
Latest Revenue (Y)
$377.71M
Latest Revenue (Q)
$11.77M
Beam Therapeutics Revenue by Period
Beam Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $377.71M | 520.01% |
| 2022-12-31 | $60.92M | 17.51% |
| 2021-12-31 | $51.84M | 215916.67% |
| 2020-12-31 | $24.00K | 33.33% |
| 2019-12-31 | $18.00K | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | - |
Beam Therapeutics generated $377.71M in revenue during NA 2023, up 520.01% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Beam Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $11.77M | 58.87% |
| 2024-03-31 | $7.41M | -97.66% |
| 2023-12-31 | $316.19M | 1739.07% |
| 2023-09-30 | $17.19M | -14.53% |
| 2023-06-30 | $20.12M | -16.90% |
| 2023-03-31 | $24.21M | 20.82% |
| 2022-12-31 | $20.04M | 26.82% |
| 2022-09-30 | $15.80M | -5.12% |
| 2022-06-30 | $16.65M | 97.49% |
| 2022-03-31 | $8.43M | -83.49% |
| 2021-12-31 | $51.07M | 6593.18% |
| 2021-09-30 | $763.00K | 12616.67% |
| 2021-06-30 | $6.00K | - |
| 2021-03-31 | $6.00K | - |
| 2020-12-31 | $6.00K | - |
| 2020-09-30 | $6.00K | - |
| 2020-06-30 | $6.00K | - |
| 2020-03-31 | $6.00K | - |
| 2019-12-31 | $6.00K | - |
| 2019-09-30 | $6.00K | - |
| 2019-06-30 | $6.00K | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | - |
Beam Therapeutics generated $11.77M in revenue during Q2 2024, up 58.87% compared to the previous quarter, and up 48.63% compared to the same period a year ago.
Beam Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals | $9.84B | $2.65B |
| BEAM | Beam Therapeutics | $377.71M | $11.77M |
| CRSP | CRISPR Therapeutics | $370.00M | $517.00K |
| DNA | Ginkgo Bioworks | $251.46M | $56.21M |
| FATE | Fate Therapeutics | $63.53M | $6.77M |
| NTLA | Intellia Therapeutics | $36.27M | $6.96M |
| CRBU | Caribou Biosciences | $34.48M | $3.46M |
| VERV | Verve Therapeutics | $11.76M | $5.70M |
| EDIT | Editas Medicine | - | - |
| PRME | Prime Medicine | - | - |
| SANA | Sana Bio | - | - |
BEAM Revenue FAQ
What is Beam Therapeutics’s yearly revenue?
Beam Therapeutics's yearly revenue for 2023 was $377.71M, representing an increase of 520.01% compared to 2022. The company's yearly revenue for 2022 was $60.92M, representing an increase of 17.51% compared to 2021. BEAM's yearly revenue for 2021 was $51.84M, representing an increase of 215916.67% compared to 2020.
What is Beam Therapeutics’s quarterly revenue?
Beam Therapeutics's quarterly revenue for Q2 2024 was $11.77M, a 58.87% increase from the previous quarter (Q1 2024), and a -41.48% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $7.41M, a -97.66% decrease from the previous quarter (Q4 2023), and a -69.39% decrease year-over-year (Q1 2023). BEAM's quarterly revenue for Q4 2023 was $316.19M, a 1739.07% increase from the previous quarter (Q3 2023), and a 1478.04% increase year-over-year (Q4 2022).
What is Beam Therapeutics’s revenue growth rate?
Beam Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 628.55%, and for the last 5 years (2019-2023) was 2098283.33%.